Real Hope For Lupus As AZ's Anifrolumab Impresses In Phase II

A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.

A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.

Only one new drug - GlaxoSmithKline's Benlysta (belimumab) - has been introduced for the treatment of lupus in the past...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category